University of Surrey

MyKnowledgeMap Announces Electronic Practice Assessment Document Approved for SCPHN Programmes

Retrieved on: 
Thursday, December 14, 2023

YORK, England, Dec. 14, 2023 /PRNewswire/ -- MyProgress is a workplace-based assessment and eportfolio tool designed specifically for medicine and healthcare education and is already used to support pre-registration nursing, nursing associate, and midwifery programmes around the capital at Pan London institutions, and at universities throughout the UK.

Key Points: 
  • Learning technology specialist MyKnowledgeMap is thrilled to announce the practice assessment document (PAD) it co-developed for SCPHN programmes has received NMC approval.
  • Nurses and midwives who take an approved SCPHN programme, and achieve the standards of proficiency, will join the SCPHN part of the NMC's register.
  • The introduction of the new standards requires all institutions with SCPHN programmes to obtain programme reapproval from the NMC for programmes starting no later than September 2024.
  • The developed practice assessment document has now been tested with practice partners and approved by the NMC following submission by one of the Pan London universities.

Onconova Expands Leadership Team with Two Key Appointments

Retrieved on: 
Tuesday, October 24, 2023

NEWTOWN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company expanded its leadership team with the naming of Dr. Victor Moyo as Chief Medical Officer (CMO), and the addition of Meena Arora as Vice President, Global Medical Affairs and Research and Development (R&D).

Key Points: 
  • Both are accomplished experts in their fields and bring significant and wide expertise in drug development.
  • I look forward to working with my colleagues at Onconova and our clinical collaborators to contribute to our mission of bringing narazaciclib and rigosertib to patients with cancer.
  • He has also held various leadership roles as Vice President of Clinical Investigations at Merrimack Pharmaceuticals and the Centocor Ortho Biotech Services, LLC division of Johnson & Johnson.
  • Prior to that, she held various leadership roles as Medical Director or Associate Medical Director, as well as roles in Investigator Research and Medical Affairs at Celgene International.

Mavenir Awarded Two 5G Consortium Projects in UK Government’s Open Networks Ecosystem Competition

Retrieved on: 
Tuesday, October 3, 2023

Mavenir, the Network Software Provider building the future of networks with cloud-native solutions that run on any cloud, has been awarded two 5G Open RAN projects, which are world firsts, as part of the UK government’s Open Networks Ecosystem Competition, targeted at the adoption of open and interoperable network technology.

Key Points: 
  • Mavenir, the Network Software Provider building the future of networks with cloud-native solutions that run on any cloud, has been awarded two 5G Open RAN projects, which are world firsts, as part of the UK government’s Open Networks Ecosystem Competition, targeted at the adoption of open and interoperable network technology.
  • HDD sites – including cities, airports, sports stadiums, and major public events – present the most challenging conditions for the technical performance of mobile networks.
  • 5G MoDE (HDD on wheels): The 5G MoDE (HDD on wheels) project is being delivered by Mavenir, Virgin Media O2, VMWare and the University of Surrey.
  • 19 projects through the Open Networks Ecosystem have been awarded as part of the competition, for more information visit the GOV.UK website .

Infleqtion Names Dr. Marco Palumbo as Director of Business Development in the United Kingdom

Retrieved on: 
Monday, October 2, 2023

OXFORD, England, Oct. 2, 2023 /PRNewswire/ -- Infleqtion, the world's quantum information company, today announced the appointment of Dr. Marco Palumbo to Director of Business Development, UK. Dr. Palumbo joins Infleqtion from Innovate UK, a non-departmental funding delivery agency of the British Government, where he served as Innovation Lead in the Quantum Technologies Challenge team, a unit responsible for more than £200m of investment in the quantum industry in the United Kingdom (UK) to date.

Key Points: 
  • OXFORD, England, Oct. 2, 2023 /PRNewswire/ -- Infleqtion , the world's quantum information company, today announced the appointment of Dr. Marco Palumbo to Director of Business Development, UK.
  • He will also develop and launch the next evolution of Infleqtion's growth strategy and foster relationships with potential customers across both public and private industries.
  • "I'm proud to welcome Dr. Marco Palumbo as the Director of Business Development at Infleqtion UK," said Scott Faris, CEO of Infleqtion.
  • "This is a time of rapid growth and development for both Infleqtion and the broader quantum industry," said Dr. Marco Palumbo, Director of Business Development, Infleqtion UK.

Net zero goal still alive, says IEA – but the world still faces major obstacles to reach it

Retrieved on: 
Wednesday, September 27, 2023

Globally, the rate at which people are installing solar panels and buying electric vehicles is “perfectly in line” with what experts have said is necessary to reach net zero emissions by 2050.

Key Points: 
  • Globally, the rate at which people are installing solar panels and buying electric vehicles is “perfectly in line” with what experts have said is necessary to reach net zero emissions by 2050.
  • That’s according to Fatih Birol, the economist who leads the world’s energy watchdog, the International Energy Agency (IEA).
  • In a recent update on humanity’s progress with cutting greenhouse gas emissions, the IEA concluded that by 2030:


The report assumes that renewable energy capacity will need to triple and replace coal, oil and gas at a rapid pace by the end of this decade to guard against catastrophic levels of warming. But despite sources like solar consistently defying even the most bullish predictions, fossil fuels have hardly budged: they supplied 82% of the world’s energy last year and 87% in 2000. Why?

Fossil fuels linger, wind power stalls

    • “[In Europe and North America] renewable energy has slowly eaten into the proportion of energy generated by fossil fuels, while all other energy sources (nuclear, hydro, biomass) have remained about the same.
    • Jansen says wind is a particularly valuable energy source during winter, when energy demand peaks.
    • McNally does not believe this setback heralds the end of cheap offshore wind, as some have claimed.

Net zero must come sooner

    • According to the IEA, “almost all countries” will also need to move their net zero target dates forward by several years.
    • A team of energy experts at Australian National University (with support from nearly 900 engineers) recently argued that Australia could hit net zero as early as 2035.
    • Australia must aim for 2035

      But in the UK at least, government policies on net zero are moving in the opposite direction.

We’ve been here before

VIAVI And Partners Awarded Funding for Three Projects In DSIT ONE Competition

Retrieved on: 
Monday, September 18, 2023

VIAVI and partners submitted successful bids for HiPer-RAN led by University of Surrey, REACH led by University of York, and ARIANE led by Telecom Infra Project (TIP).

Key Points: 
  • VIAVI and partners submitted successful bids for HiPer-RAN led by University of Surrey, REACH led by University of York, and ARIANE led by Telecom Infra Project (TIP).
  • VIAVI will lead the work on integration, testing, deployment and trial of the entire HiPer-RAN solution for a number of scenarios and use cases.
  • VIAVI TeraVM RIC Test will support testing of xApps and rApps for mMIMO Apps, including traffic shaping, beam formation and energy efficiency.
  • "VIAVI is proud to be a partner in the DSIT ONE flagship program for Open Network R&D in the U.K.," said Ian Langley, Senior Vice President, Wireless Business Unit, VIAVI.

Keysight Awarded Two Open Networks Ecosystem Competition Grants from UK Government

Retrieved on: 
Friday, September 15, 2023

Keysight Technologies, Inc. (NYSE: KEYS) has been awarded two Open Networks Ecosystem (ONE) competition grants from the UK Government’s Department for Science, Innovation and Technology in partnership with 5G RuralDorset, Arm, British Telecom, the University of Surrey, Virgin Media O2, and Vodafone.

Key Points: 
  • Keysight Technologies, Inc. (NYSE: KEYS) has been awarded two Open Networks Ecosystem (ONE) competition grants from the UK Government’s Department for Science, Innovation and Technology in partnership with 5G RuralDorset, Arm, British Telecom, the University of Surrey, Virgin Media O2, and Vodafone.
  • Launched in early 2023, the ONE competition seeks to diversify the supply chain for the country’s wireless networks while advancing Open Radio Access Network (RAN) architectures.
  • 5G RuralDorset Program: Working with 5G RuralDorset, Vodafone, Arm, and other industry partners, Keysight will jointly deploy an end-to-end Open RAN network by co-developing various Open RAN network components, specifically in the areas of RIC artificial intelligence / machine learning and security algorithms.
  • Both projects will use the Keysight Open RAN Architect (KORA) solution to emulate Open RAN networks to enable the testing and optimization of RIC and associated software.

EQS-News: International Experts Highlight Demand for Diagnostic Innovations as PenKid's Research and Real-World Data Fuels Quest for Improved RRT Liberation Tools

Retrieved on: 
Wednesday, September 6, 2023

Recently published scientific data affirms that penKid remains informative under acute renal replacement therapy (RRT) and can identify patients for successful liberation.

Key Points: 
  • Recently published scientific data affirms that penKid remains informative under acute renal replacement therapy (RRT) and can identify patients for successful liberation.
  • RRT, a common practice in Intensive Care Units (ICUs), has long relied on clinical observations for stop decisions.
  • However, the lack of a dependable biomarker poses challenges in accurately assessing when to discontinue RRT.
  • Considering this, leading experts from the field have discussed in a recent advisory board the importance of identifying the right tools to improve the outcomes in AKI.

All the evidence against the UK’s plans to expand oil and gas drilling

Retrieved on: 
Wednesday, August 2, 2023

How many new oil and gas fields can the climate sustain?

Key Points: 
  • How many new oil and gas fields can the climate sustain?
  • “We cannot safely set fire to all the fuel we’ve already found, so why look for more?” he asks.
  • Read more:
    We should ban all new oil and gas fields

    This roundup of The Conversation’s coverage of how more oil and gas drilling will affect climate change comes from our weekly climate action newsletter.

  • Our analysis also showed that global oil and gas production must peak immediately and fall by 3% each year until mid-century,” they say.
  • And the UK isn’t obliged to keep using oil and gas until 2050 as Sunak suggests.

The real cost of carbon

Biosero Appoints Rob Harkness as Chief Technology Officer

Retrieved on: 
Tuesday, August 1, 2023

Biosero, Inc., developer of laboratory automation solutions to orchestrate scientific discoveries, today announced the promotion of Rob Harkness, PhD, to the position of Chief Technology Officer.

Key Points: 
  • Biosero, Inc., developer of laboratory automation solutions to orchestrate scientific discoveries, today announced the promotion of Rob Harkness, PhD, to the position of Chief Technology Officer.
  • “In the three years Rob has been at Biosero, he has consistently impressed me with his technical competencies, future vision, and commitment to ensuring customer success,” said Tom Gilman, President and CEO at Biosero.
  • “Rob has an extensive background in laboratory automation and a keen sense of what customers need to accelerate their science.
  • Prior to Biosero, Dr. Harkness held roles of increasing responsibility at automation and robotics companies such as CyBio, Astech Projects, and Peak Analysis and Automation.